Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C
Introduction and Aims: Insulin-like growth factor 1 is modulated by the insulin-like growth factor-binding proteins (IGFBPs) that are synthesized in the liver. The aim of the present study was to evaluate the concentrations of IGFBPs 1–7 in patients with chronic hepatitis C and study their associati...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | Revista de Gastroenterología de México (English Edition) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2255534X20300013 |
id |
doaj-554a2a4c29604f11bdf1a09461d19191 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
D. Rosique-Oramas M. Martínez-Castillo A. Raya Z. Medina-Ávila F. Aragón J. Limón-Castillo A. Hernández-Barragán A. Santoyo E. Montalvo-Javé J.L. Pérez-Hernández F. Higuera-de la Tijera A. Torre D. Kershenobich G. Gutiérrez-Reyes |
spellingShingle |
D. Rosique-Oramas M. Martínez-Castillo A. Raya Z. Medina-Ávila F. Aragón J. Limón-Castillo A. Hernández-Barragán A. Santoyo E. Montalvo-Javé J.L. Pérez-Hernández F. Higuera-de la Tijera A. Torre D. Kershenobich G. Gutiérrez-Reyes Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C Revista de Gastroenterología de México (English Edition) Fibrosis hepática Hepatitis C crónica IGFBP Biomarcadores |
author_facet |
D. Rosique-Oramas M. Martínez-Castillo A. Raya Z. Medina-Ávila F. Aragón J. Limón-Castillo A. Hernández-Barragán A. Santoyo E. Montalvo-Javé J.L. Pérez-Hernández F. Higuera-de la Tijera A. Torre D. Kershenobich G. Gutiérrez-Reyes |
author_sort |
D. Rosique-Oramas |
title |
Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C |
title_short |
Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C |
title_full |
Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C |
title_fullStr |
Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C |
title_full_unstemmed |
Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C |
title_sort |
production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis c |
publisher |
Elsevier |
series |
Revista de Gastroenterología de México (English Edition) |
issn |
2255-534X |
publishDate |
2020-10-01 |
description |
Introduction and Aims: Insulin-like growth factor 1 is modulated by the insulin-like growth factor-binding proteins (IGFBPs) that are synthesized in the liver. The aim of the present study was to evaluate the concentrations of IGFBPs 1–7 in patients with chronic hepatitis C and study their association with fibrosis stage. Patients and methods: A prospective, cross-sectional study was conducted that included patients with chronic hepatitis C. The stages of fibrosis were determined through FibroTest and FibroScan and the patients were compared with a control group. Serum levels of IGFBPs 1–7 were quantified through multiple suspension arrays. The Kruskal-Wallis test, Mann-Whitney U test, Spearman’s correlation, and ROC curves were used for the statistical analysis. Results: Upon comparing the patients and controls, the highest concentrations were found in IGFBPs 1, 2, 4, and 7 (p = 0.02, 0.002, 0.008, and <0.001, respectively). IGFBP-3 levels had a tendency to be lower in the patients (p = 0.066), whereas values were similar between patients and controls for IGFBP-5 and 6 (p = 0.786 and p = 0.244, respectively). Of the seven IGFBPs, IGFBP-3 concentrations were the highest. There were significant differences between fibrosis stages for IGFBP-5 and IGFBP-7. Conclusion: IGFBPs play a relevant role in the fibrotic process in liver damage. IGFBP-7, in particular, differentiates fibrosis stages, making it a potential serum biomarker. Resumen: Antecedentes y objetivos: El factor de crecimiento tipo insulinoide 1 es modulado por las proteínas de unión al factor de crecimiento de tipo insulinoide (IGFBPs), dichas proteínas son sintetizadas el hígado. El objetivo de este trabajo fue evaluar la concentración de IGFBPs 1–7 en pacientes con hepatitis C crónica y estudiar la asociación con el grado de fibrosis. Pacientes y Métodos: Estudio prospectivo, transversal. Se incluyeron pacientes con hepatitis C crónica, el grado de fibrosis se determinó por medio de Fibrotest y Fibroscan, los pacientes se compararon con un grupo control. Los niveles séricos de IGFBPs 1–7 fueron cuantificados por arreglo en suspensión múltiple. Para el análisis estadístico se utilizó Kruskal Wallis, U de Mann Whitney, correlación de Spearman y curvas ROC. Resultados: Al comparar entre pacientes y controles, las concentraciones fueron más altas en las IGFBPs:1,2, 4 y 7(p = 0.02, 0.002, 0.008y<0.001 respectivamente). IGFBP-3 con tendencia a ser menor en los pacientes (p = 0.066). Mientras que la IGFBP-5y 6 tuvieron valores similares entre pacientes y controles (p = 0.786 y p = 0.244 respectivamente). De las siete IGFBPs, las concentraciones de IGFBP-3 fueron las más altas. De acuerdo con el grado de fibrosis, se encontraron diferencias significativas en IGFBP-5 e IGFBP-7. Conclusión: Las IGFBPs tienen papel relevante en el proceso de daño fibrogénico hepático, en especial la IGFBP-7 participa de manera diferencial en los estadios de fibrosis, por lo que puede ser un potencial biomarcador sérico. |
topic |
Fibrosis hepática Hepatitis C crónica IGFBP Biomarcadores |
url |
http://www.sciencedirect.com/science/article/pii/S2255534X20300013 |
work_keys_str_mv |
AT drosiqueoramas productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT mmartinezcastillo productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT araya productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT zmedinaavila productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT faragon productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT jlimoncastillo productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT ahernandezbarragan productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT asantoyo productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT emontalvojave productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT jlperezhernandez productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT fhigueradelatijera productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT atorre productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT dkershenobich productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc AT ggutierrezreyes productionofinsulinlikegrowthfactorbindingproteinsduringthedevelopmentofhepaticfibrosisduetochronichepatitisc |
_version_ |
1724438144569311232 |
spelling |
doaj-554a2a4c29604f11bdf1a09461d191912020-11-25T04:04:00ZengElsevierRevista de Gastroenterología de México (English Edition)2255-534X2020-10-01854390398Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis CD. Rosique-Oramas0M. Martínez-Castillo1A. Raya2Z. Medina-Ávila3F. Aragón4J. Limón-Castillo5A. Hernández-Barragán6A. Santoyo7E. Montalvo-Javé8J.L. Pérez-Hernández9F. Higuera-de la Tijera10A. Torre11D. Kershenobich12G. Gutiérrez-Reyes13Laboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, MexicoLaboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, MexicoLaboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, MexicoLaboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, MexicoLaboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, MexicoLaboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, MexicoLaboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, MexicoLaboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, MexicoClínica Hepato-Pancreato-Biliar, Servicio de Cirugía General, Hospital General de México Dr. Eduardo Liceaga, Departamento de Cirugía, Facultad de Medicina, UNAM, Mexico City, MexicoDepartamento de Gastroenterología, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoDepartamento de Gastroenterología, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoUnidad de Hepatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoUnidad de Hepatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoLaboratorio de Hígado, Páncreas y Motilidad (HIPAM), Unidad de Investigación en Medicina Experimental, Facultad de Medicina, UNAM, Mexico City, Mexico; Corresponding author.Introduction and Aims: Insulin-like growth factor 1 is modulated by the insulin-like growth factor-binding proteins (IGFBPs) that are synthesized in the liver. The aim of the present study was to evaluate the concentrations of IGFBPs 1–7 in patients with chronic hepatitis C and study their association with fibrosis stage. Patients and methods: A prospective, cross-sectional study was conducted that included patients with chronic hepatitis C. The stages of fibrosis were determined through FibroTest and FibroScan and the patients were compared with a control group. Serum levels of IGFBPs 1–7 were quantified through multiple suspension arrays. The Kruskal-Wallis test, Mann-Whitney U test, Spearman’s correlation, and ROC curves were used for the statistical analysis. Results: Upon comparing the patients and controls, the highest concentrations were found in IGFBPs 1, 2, 4, and 7 (p = 0.02, 0.002, 0.008, and <0.001, respectively). IGFBP-3 levels had a tendency to be lower in the patients (p = 0.066), whereas values were similar between patients and controls for IGFBP-5 and 6 (p = 0.786 and p = 0.244, respectively). Of the seven IGFBPs, IGFBP-3 concentrations were the highest. There were significant differences between fibrosis stages for IGFBP-5 and IGFBP-7. Conclusion: IGFBPs play a relevant role in the fibrotic process in liver damage. IGFBP-7, in particular, differentiates fibrosis stages, making it a potential serum biomarker. Resumen: Antecedentes y objetivos: El factor de crecimiento tipo insulinoide 1 es modulado por las proteínas de unión al factor de crecimiento de tipo insulinoide (IGFBPs), dichas proteínas son sintetizadas el hígado. El objetivo de este trabajo fue evaluar la concentración de IGFBPs 1–7 en pacientes con hepatitis C crónica y estudiar la asociación con el grado de fibrosis. Pacientes y Métodos: Estudio prospectivo, transversal. Se incluyeron pacientes con hepatitis C crónica, el grado de fibrosis se determinó por medio de Fibrotest y Fibroscan, los pacientes se compararon con un grupo control. Los niveles séricos de IGFBPs 1–7 fueron cuantificados por arreglo en suspensión múltiple. Para el análisis estadístico se utilizó Kruskal Wallis, U de Mann Whitney, correlación de Spearman y curvas ROC. Resultados: Al comparar entre pacientes y controles, las concentraciones fueron más altas en las IGFBPs:1,2, 4 y 7(p = 0.02, 0.002, 0.008y<0.001 respectivamente). IGFBP-3 con tendencia a ser menor en los pacientes (p = 0.066). Mientras que la IGFBP-5y 6 tuvieron valores similares entre pacientes y controles (p = 0.786 y p = 0.244 respectivamente). De las siete IGFBPs, las concentraciones de IGFBP-3 fueron las más altas. De acuerdo con el grado de fibrosis, se encontraron diferencias significativas en IGFBP-5 e IGFBP-7. Conclusión: Las IGFBPs tienen papel relevante en el proceso de daño fibrogénico hepático, en especial la IGFBP-7 participa de manera diferencial en los estadios de fibrosis, por lo que puede ser un potencial biomarcador sérico.http://www.sciencedirect.com/science/article/pii/S2255534X20300013Fibrosis hepáticaHepatitis C crónicaIGFBPBiomarcadores |